Recombinant interleukin 3 induces interleukin 2 receptor expression on early myeloid cells in normal human bone marrow
- PMID: 1371965
Recombinant interleukin 3 induces interleukin 2 receptor expression on early myeloid cells in normal human bone marrow
Abstract
Human interleukin 3 (IL-3) is a multipotential cytokine that supports the growth of early hematopoietic progenitors and promotes their response to other, later-acting cytokines. We found that IL-3 was able to induce the expression of interleukin 2 (IL-2) receptor (IL-2R) (CD25) on a subset of early myeloid cells in normal human bone marrow that had been first depleted of mature hematopoietic cells and E-rosette-positive T cells by treatment with soybean lectin and sheep erythrocytes (SBA-E-BM). Immunofluorescence analysis revealed that the CD25+ cells were contained almost entirely within the lymphoblastoid gate of the IL-3-cultured marrow. CD25 was undetectable on freshly isolated marrow and less than 10% CD25+ cells could be detected following liquid culture at 37 degrees C in the presence of 10% human serum, 10% fetal calf serum, or under serum-free conditions. Addition of IL-3 (100 U/ml) significantly increased the expression of CD25 to 37%, 31%, and 24%, respectively. CD25 could also be induced by granulocyte-macrophage colony-stimulating factor (GM-CSF), but no IL-2R was detectable following exposure to granulocyte colony-stimulating factor (G-CSF), macrophage colony-stimulating factor (M-CSF), interleukin 1 (IL-1), interleukin 4 (IL-4), or IL-2. Expression of CD25 was dependent on the dose of IL-3 or GM-CSF added and was maximal within 24 h of exposure. Two-color immunofluorescence analysis demonstrated that CD25 was not expressed by cells of lymphoid lineage or by mature monocytes, but rather was present on cells that coexpressed CD13, CD33, CD34, MY8, and HLA-DR, and that lacked CD14 or CD11b, thus placing the CD25+ cells at or near the myeloblast stage of differentiation. An identical phenotype was found for CD25+ cells induced by GM-CSF. Cycloheximide completely inhibited the IL-3-induced expression of CD25, indicating the necessity for protein synthesis, and although most of the CD25+ cells were in G0/G1 phase, 25% of the cells were in S or G2M phase, indicating that receptor expression was not cell-cycle dependent. The p75 chain of IL-2R was not detected on the CD25+ cells. IL-3 was also found to directly induce CD25 in greater than 46% of SBA-E-BM enriched for CD34+ cells by panning. Consistent with the expression of only p55 IL-2R, the functional activity of IL-2 on enriched CD34+ cells exposed to IL-3 could not be demonstrated in either granulocyte-macrophage colony-forming unit (CFU-GM) assays or proliferation assays.(ABSTRACT TRUNCATED AT 400 WORDS)
Similar articles
-
Interleukin-11 stimulates the proliferation of human hematopoietic CD34+ and CD34+CD33-DR- cells and synergizes with stem cell factor, interleukin-3, and granulocyte-macrophage colony-stimulating factor.Exp Hematol. 1993 Dec;21(13):1668-72. Exp Hematol. 1993. PMID: 7694867
-
Interactions of tumor necrosis factor with granulocyte-macrophage colony-stimulating factor and other cytokines in the regulation of dendritic cell growth in vitro from early bipotent CD34+ progenitors in human bone marrow.J Immunol. 1992 Oct 15;149(8):2681-8. J Immunol. 1992. PMID: 1383322
-
Effect of stem cell factor (c-kit ligand), granulocyte-macrophage colony stimulating factor and interleukin 3 on hematopoietic progenitors in human long-term bone marrow cultures.Stem Cells. 1993 Sep;11(5):435-44. doi: 10.1002/stem.5530110511. Stem Cells. 1993. PMID: 7694721
-
Control of proliferation by myeloid growth factors.Biochem Soc Trans. 1991 Apr;19(2):307-15. doi: 10.1042/bst0190307. Biochem Soc Trans. 1991. PMID: 1716228 Review.
-
Myeloid cell kinetics in response to haemopoietic growth factors.Baillieres Clin Haematol. 1992 Jul;5(3):533-50. doi: 10.1016/s0950-3536(11)80006-5. Baillieres Clin Haematol. 1992. PMID: 1281018 Review.
Cited by
-
Induction of soluble IL-2 receptor in patients with myelodysplastic syndromes undergoing high-dose interleukin-3 treatment.Ann Hematol. 1994 Apr;68(4):167-70. doi: 10.1007/BF01834361. Ann Hematol. 1994. PMID: 8003557 Clinical Trial.
-
Demonstration of early functional compromise of bone marrow derived hematopoietic progenitor cells during bovine neonatal pancytopenia through in vitro culture of bone marrow biopsies.BMC Res Notes. 2012 Oct 30;5:599. doi: 10.1186/1756-0500-5-599. BMC Res Notes. 2012. PMID: 23110710 Free PMC article.
-
Recombinant immunotoxins for the treatment of chemoresistant hematologic malignancies.Curr Pharm Des. 2009;15(23):2652-64. doi: 10.2174/138161209788923949. Curr Pharm Des. 2009. PMID: 19689336 Free PMC article. Review.
-
Anoxia Rapidly Induces Changes in Expression of a Large and Diverse Set of Genes in Endothelial Cells.Int J Mol Sci. 2023 Mar 8;24(6):5157. doi: 10.3390/ijms24065157. Int J Mol Sci. 2023. PMID: 36982232 Free PMC article.
-
Recombinant immunotoxins containing truncated bacterial toxins for the treatment of hematologic malignancies.BioDrugs. 2009;23(1):1-13. doi: 10.2165/00063030-200923010-00001. BioDrugs. 2009. PMID: 19344187 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Medical
Research Materials
Miscellaneous